Skip to main content
Sabrin H. Albeituni on Muck Rack

Sabrin H. Albeituni

As seen in: Frontiers, Blood, The Journal of Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sabrin H.

Contact Sabrin H., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A predictive model for identifying secondary underlying diseases of hemophagocytic lymphohistiocytosis

|
By Wei-bo Gao, Sabrin H. Albeituni, Yasuhiro Shimojima, Dipendra Khadka
| Frontiers
1Department of Emergency, Peking University People’s Hospital, Beijing, China 2Peking University People’s Hospital, Peking University Institute of Haematology, Beijing, China 3National Clinical Research Center for Haematologic Disease, Beijing, China 4Trauma Center, Peking University People’s Hospital, Beijing, China Background: Secondary hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening disease of immune hyperactivation that arises in the context of infectious,...
Open in Who Shared Issue with article?

Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS

|
By Randy Q Cron, Michelle Hermiston, Sabrin H. Albeituni, Xiang Liu
| Frontiers
Xiang Liu, Xueling Zhu, Xiaotang Zhou, Yirui Xie, Dairong Xiang, Zhikai Wan, Ying Huang and Biao Zhu* The Department of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China Hemophagocytic lymphohistiocytosis (HLH) is a fatal...
Open in Who Shared Issue with article?

Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis

|
By Sabrin H. Albeituni, Katherine Verbist, Heather Tillman, Paige E. Tedrick
| Blood Verified
Sabrin Albeituni, Katherine C. Verbist, Paige E. Tedrick, Heather Tillman, Jennifer Picarsic, Rachel Bassett and Kim E. Nichols Blood 2019 134:147-159; doi: https://doi.org/10.1182/blood.2019000761 Key Points The JAK1/2 inhibitor ruxolitinib dampens inflammation in HLH via IFN-γ–dependent and –independent mechanisms. Ruxolitinib exerts its beneficial effects in HLH by targeting T-cell and neutrophil activation and tissue infiltration.
Open in Who Shared Issue with article?
See all 4 articles